TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19695832

Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (NT group) received individual nutritional counseling and interventions, including oral nutritional supplements if appropriate.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral nutritional supplement group (ONS group) received oral nutritional supplements in addition to hospital meals without further instruction or counseling.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (NT group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral nutritional supplement group (ONS group)
Number of subjects: 36
Study: 18840822

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 15841829

Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 30
Study: 12432322

Group type: EXPERIMENTAL
Intervention: Volume Diffusive Respirator (VDR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional ventilation (PCV)
Number of subjects: 64
Study: 10734522

Group type: EXPERIMENTAL
Intervention: ParaSight-F test (PFT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Microscopic slide readings
Number of subjects: 382
Study: 8750403

Group type: EXPERIMENTAL
Intervention: PGE1 at 0.06 micro g/kg per minute for 3 postoperative days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 35
Study: 1776410

Group type: EXPERIMENTAL
Intervention: Captopril (ACE-inhibition)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6130065

Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Diazepam (20 mg)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Clorazepate (24 mg)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 31891449

Group type: EXPERIMENTAL
Intervention: roxadustat (initial dose, 50 or 70 mg) for 24 weeks (ESA-Naïve Study)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: roxadustat (initial dose, 70 or 100 mg based on prior ESA dose) for 52 weeks (ESA-Converted Study)
Number of subjects: 239
Study: 31253071

Group type: EXPERIMENTAL
Intervention: Full major statement in TV ad
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Edited version of TV ad (only serious and actionable risks)
Number of subjects: 1000
Study: 27975236

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 at 10,000 IU daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-dose vitamin D3 at 1000 IU daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose vitamin D3
Number of subjects: 34
Study: 26194253

Group type: EXPERIMENTAL
Intervention: Energized dissection (ED)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-Energized dissection (non-ED)
Number of subjects: 100
Study: 24400643

Group type: EXPERIMENTAL
Intervention: Intervention group receiving a half-day training in heart failure management and structured up-titration scheme.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual group (control).
Number of subjects: 0
Study: 22348695

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open-flap debridement
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) with open-flap debridement
Number of subjects: 90

Group type: COMPARATOR
Intervention: Open-flap debridement alone (Control)
Number of subjects: 90
Study: 19219569

Group type: EXPERIMENTAL
Intervention: HHH therapy administered over 3-9 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 12
Study: 17283283

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg oral)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.9 mg intravenous bolus followed by 0.0102 mg/min infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 22
Study: 15502053

Group type: EXPERIMENTAL
Intervention: Clinically relevant articles
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Journal Impact Factor
Number of subjects: 1379
Study: 11680670

Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS 20 mg tablet (Test)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Omeprazole MUPS 20 mg tablet (Reference)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both formulations (Test and Reference)
Number of subjects: 38
Study: 9636963

Group type: EXPERIMENTAL
Intervention: Barath Cutting Balloon (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional balloons (group B)
Number of subjects: 64
Study: 7866263

Group type: EXPERIMENTAL
Intervention: Acetylcholine 1.0%
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.02%
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Acetylcholine 1.0% plus Thymoxamine 0.02%
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 2672673

Group type: EXPERIMENTAL
Intervention: Phadirect Strep A test
Number of subjects: 67

Group type: COMPARATOR
Intervention: Bacteriologic investigation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Coagglutination test for SB serotyping
Number of subjects: 67
Study: 616215

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30535338

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours of sleep between 3:00 am and 7:00 am)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (no sleep at all)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regular sleep duration (8 hours of sleep between 11:00 pm and 7:00 am)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sleep loss (both sleep restriction and deprivation)
Number of subjects: 15
Study: 27913872

Group type: EXPERIMENTAL
Intervention: 4 g/day of fish oil (2.4 g n-3 PUFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 100
Study: 25765839

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Erigerontis hydroxybenzenes injection (EHI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of EHI
Number of subjects: 40
Study: 24065423

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia with leukocyte reduction filters
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blood cardioplegia without leukocyte reduction filters (Group II)
Number of subjects: 40
Study: 21849601

Group type: EXPERIMENTAL
Intervention: partially hydrolyzed whey (pHF-W)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed whey (eHF-W)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed casein (eHF-C)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: cow-milk formula (CMF)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: breastfeeding (BF)
Number of subjects: 1840
Study: 19756742

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment for 6 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 68
Study: 18024838

Group type: EXPERIMENTAL
Intervention: Iceman
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: EBIce
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ankle Cryo/Cuff
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cryotherapy devices (all)
Number of subjects: 4
Study: 15375524

Group type: EXPERIMENTAL
Intervention: 5‐FU + LV for 6 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: 5‐FU + LVZ for 12 months
Number of subjects: 150
Study: 11478761

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 100
Study: 9596318

Group type: EXPERIMENTAL
Intervention: Dobutamine 3 microg/kg/min
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dobutamine 5 microg/kg/min
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Three CO measurements for VO2 and DO2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Weighting the slope to the observed change in DO2
Number of subjects: 27
Study: 7835264

Group type: EXPERIMENTAL
Intervention: Intraumbilical infusion through a mucus aspiration catheter
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intraumbilical infusion by an 18 gauge needle (direct injection)
Number of subjects: 21
Study: 2974713

Group type: EXPERIMENTAL
Intervention: Sufentanil 3.75‐15 micrograms kg‐1 with nitrous oxide and midazolam
Number of subjects: 30
Study: 29863378

Group type: EXPERIMENTAL
Intervention: Hierarchical neural network model with top‐down and lateral synaptic connections, multiple synaptic contacts, and spike-timing-dependent plasticity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurons representing binding relationships between low-level and high-level visual features through visually guided learning.
Number of subjects: 0
Study: 26973347

Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban OD for 45 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg fondaparinux OD for 45 days
Number of subjects: 0
Study: 24925924

Group type: EXPERIMENTAL
Intervention: New diagnosis of COPD (screening)
Number of subjects: 386
Study: 22641239

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 36 months
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 20554607

Group type: EXPERIMENTAL
Intervention: Increased subretinal tissue volume
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Subretinal fluid (SRF) volume
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Increased retinal thickness at the foveal center
Number of subjects: 122
Study: 19029470

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 112
Study: 15753273

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (0.6 mg/kg, max 10 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12531351

Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle (OMV) vaccines
Number of subjects: 172000
Study: 11240955

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 14
Study: 9271963

Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1860
Study: 8516659

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3565812

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02 or 0.05 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (0.02, 0.04, 0.1, or 0.2 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4 or 1 mg/kg)
Number of subjects: 120
Study: 31273506

Group type: EXPERIMENTAL
Intervention: Hyaluronan formulation (study cream, S)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cream (placebo, P)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Independent panel assessment
Number of subjects: 30
Study: 28943477

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (including self-efficacy component)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 275
Study: 27879359

Group type: EXPERIMENTAL
Intervention: DECIDE Self‐Study
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: DECIDE Individual
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: DECIDE Group
Number of subjects: 182

Group type: COMPARATOR
Intervention: Enhanced UC
Number of subjects: 182
Study: 25567120

Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with rPNS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS combined with rPNS
Number of subjects: 20
Study: 22796108

Group type: EXPERIMENTAL
Intervention: Modafinil, 200 mg, once daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Escitalopram, 20 mg, once daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Modafinil + Escitalopram, once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20871178

Group type: EXPERIMENTAL
Intervention: Office noise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mozart's music
Number of subjects: 60
Study: 17899310

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (100 mJ/pulse; 15 Hz; 1.5 W, 60 s, 141.5 J/cm(2))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 17
Study: 16798442

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with intermittent 10‐mL boluses of 0.125% levobupivacaine into the epidural space and physiologic saline into the surgical wound
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incisional analgesia with intermittent 10‐mL boluses of 0.25% levobupivacaine into the wound and epidural saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 14725383

Group type: EXPERIMENTAL
Intervention: 2% zinc citrate, 0.3% Triclosan dentifrice
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 40
Study: 10762286

Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075 to 0.6 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 to 3 mg/week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinagolide and Cabergoline
Number of subjects: 20
Study: 9101848

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 963

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 963
Study: 30669022

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 21
Study: 29717291

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 65
Study: 26716357

Group type: EXPERIMENTAL
Intervention: Controlled-inhalation nebulizer (AKITA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional nebulizer (PARI-LC Plus)
Number of subjects: 10
Study: 24698199

Group type: EXPERIMENTAL
Intervention: 4-hour hemodialysis (HD4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 4-hour hemodiafiltration (HDF4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 8-hour hemodialysis (HD8)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 8-hour hemodiafiltration (HDF8)
Number of subjects: 13
Study: 22759069

Group type: EXPERIMENTAL
Intervention: RIT (regenerative injection therapy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise therapy only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RIT after exercise therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (after 36 weeks)
Number of subjects: 36
Study: 18482589

Group type: EXPERIMENTAL
Intervention: I-FOBT (OC-Sensor)
Number of subjects: 20623

Group type: COMPARATOR
Intervention: G-FOBT (Hemoccult-II)
Number of subjects: 20623
Study: 16518579

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Prednisolone (10 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12901730

Group type: EXPERIMENTAL
Intervention: Oral nicorandil-induced lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinical criteria used by physicians
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absence of yellow-based ulceration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Linear shape of lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absence of inflammatory halo
Number of subjects: 60
Study: 11180878

Group type: EXPERIMENTAL
Intervention: 6.9% branched chain amino acid (BCAA) solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 30
Study: 9309356

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Exposure
Number of subjects: 39
Study: 7828459

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 92
Study: 3518107

Group type: EXPERIMENTAL
Intervention: Abstention from MTX-containing beverages
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Abstention from alcohol
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Abstention from MTX and alcohol
Number of subjects: 192

Group type: COMPARATOR
Intervention: No dietary advice
Number of subjects: 192
Study: 29899395

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with cisplatin (50 mg/m2) and etoposide (100 mg/m2) followed by intravenous chemotherapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Intravenous chemotherapy alone
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with cisplatin and etoposide
Number of subjects: 215
Study: 27566745

Group type: EXPERIMENTAL
Intervention: Nasogastric tubes (NGT)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Poststroke pneumonia (PSP)
Number of subjects: 1217
Study: 22956633

Group type: EXPERIMENTAL
Intervention: Telephone-delivered health coaching (ProActive Heart)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study: 22250141

Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D supplementation every 4 weeks for 1 year
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 21190551

Group type: COMPARATOR
Intervention: NDUFV2 gene promoter variants (rs6506640 and rs1156044)
Number of subjects: 529
Study: 18237663

Group type: COMPARATOR
Intervention: Intravenous catheter collection technique
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Venipuncture collection technique
Number of subjects: 853
Study: 16247245

Group type: EXPERIMENTAL
Intervention: Deep Relief gel (3% menthol)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ibuleve gel (only ibuprofen)
Number of subjects: 2
Study: 14585881

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 24
Study: 11885174

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)-cylinder
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Titanium-alloy screw
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Commercially pure titanium screw
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Non-HA implants
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: HA-grooved implant
Number of subjects: 2900
Study: 8599319

Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene supplementation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 1568865

Group type: EXPERIMENTAL
Intervention: Inhaled ketanserin, 10 mg given 30 min before test
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3907687

Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Histological involvement of resected intrathoracic nodes
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Histological type of the tumour
Number of subjects: 726
Study: 30588322

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg every 4 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 27631883

Group type: EXPERIMENTAL
Intervention: Baseline amino-terminal pro-B type natriuretic peptide (NT-proBNP)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Edema
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Percent time with NT-proBNP ≥1000 pg/mL (serial measurement)
Number of subjects: 108
Study: 25624376

Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration (0.2 mL every 3 hours for 3 days)
Number of subjects: 48
Study: 22949570

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 20049961

Group type: EXPERIMENTAL
Intervention: Oral rapamycin (2 mg/day for 30 days)
Number of subjects: 80
Study: 18509181

Group type: EXPERIMENTAL
Intervention: Fluorouracil and irinotecan
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Fluorouracil and oxaliplatin
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Fluorouracil, irinotecan, and oxaliplatin (first-line combination chemotherapy)
Number of subjects: 1628
Study: 17043133

Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment program
Number of subjects: 260

Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 260
Study: 14520110

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP, Flonase)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal control nasal turbinate tissues
Number of subjects: 16
Study: 10878070

Group type: EXPERIMENTAL
Intervention: COBAS HCV MONITOR version 2.0
Number of subjects: 174

Group type: COMPARATOR
Intervention: AMPLICOR HCV MONITOR version 1.0
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: QUANTIPLEX HCV RNA version 2.0
Number of subjects: 174
Study: 10437173

Group type: EXPERIMENTAL
Intervention: Wu Zi Yan Zong (WZYZ) fluid
Number of subjects: 0
Study: 1441867

Group type: EXPERIMENTAL
Intervention: Thiopentone 5‐6 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 2‐3 mg/kg
Number of subjects: 30
Study: 3954815

Group type: EXPERIMENTAL
Intervention: tasuldine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: acetylcysteine
Number of subjects: 15

Group type: COMPARATOR
Intervention: control
Number of subjects: 15
Study: 31744637

Group type: EXPERIMENTAL
Intervention: Elective induction at 39 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31644588

Group type: EXPERIMENTAL
Intervention: Digital decision support tool
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 89